Early Findings Highlight Promising Outcomes With REGN5458 in Relapsed/Refractory Multiple Myeloma

Article

Patients with relapsed/refractory multiple myeloma experienced promising responses with REGN5458.

Findings from a phase 1/2 trial (NCT03761108) highlighted timely and promising responses among patients with heavily pre-treated relapsed/refractory multiple myeloma who were treated with REGN5458.

Data from the study, which were presented at the 2022 European Hematology Association Congress, indicated the overall response rate (ORR) was 51% among patients who were treated with the monotherapy. Moreover, investigators reported a very good partial response (VGPR) of better rate of 86%, of which 43% were complete responses (CR) or better.

When assessing responses by dose level, investigators reported that ORR was 29% in the 3 mg to 12 mg cohort, 48% in the 24 mg to 96 mg cohort, and 75% in the 200 mg to 800 mg cohort. Moreover, in the 3 mg to 12 mg arm, the PR rate was 4%, CR rate was 13%, and stringent CR (sCR) rate was 13%; in the 24 mg to 96 mg arm, the VGPR rate was 24%, CR rate was 4%, and sCR rate was 20%; and in the 200 mg to 800 mg arm, the PR rate was 17%, VGPR rate was 42%, CR rate was 8% and sCR rate was 8%.

This was a first-in-human, open-label trial assessing the use of REGN5458, a BCMA- and CD3-directed bispecific antibody capable of achieving cytotoxicity on BCMA-expressing cancer cells by targeting T-cell effector function. A total of 9 doses of the agent were evaluated using a 4 + 3 design, including 3 mg (n = 4), 6 mg (n = 10), 12 mg (n = 10), 24 mg (n = 10), 48 mg (n = 7), 96 mg (n = 8), 200 mg (n = 12), 400 mg (n = 8), and 800 mg (n = 4). A double step-up dosing strategy was used to administer the intravenous agent, which entailed an initial dose during week 1, a step-up dose in week 2, and a full cohort dose during week 3.

Patients had a median time to response of 1 month, with most responses (70%) taking place within 2 months of treatment. The estimated median duration of response was not reached and the probability of responders maintaining a response at 8 months was 90.2%.

In terms of safety, the most common grade 3 or higher hematologic treatment-emergent adverse effects (TEAEs) occurring in at least 20% of patients or more included pneumonia (11%), back pain (5%), pyrexia (4%), fatigue (3%), diarrhea (3%), headache (3%), and chills (1%).

Although 4% of patients experienced grade 2 immune effector cell–associated neurotoxicity syndrome, there were no grade 3 events. Additionally, 38% of patients developed cytokine release syndrome (CRS), although most events were grade 1 in severity. A total of 3 patients had grade 2 CRS and no grade 3 or higher events were reported. Seven percent of patients experienced grade 5 AEs, including sepsis, COVID-19, and pneumonia.

Reference

Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of CRS with REGN5458, a BCMAXCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. Abstract S189.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
Related Content